Mission Produce earnings up, buoyed by rising avocado consumption
Rising avocado sales helped Mission Produce turn a profit in the second quarter of 2021 after posting a loss a year earlier. The Oxnard-based avocado distributor generated earnings of $7.4 million, or 10 cents per diluted share, for the quarter ended April 30, the company announced on June 10. In the same quarter last year, Read More →
Limoneira, Calavo both report earnings growth as produce industry continues recovery
Santa Paula-based agribusinesses Limoneira and Calavo Growers both reported positive earnings in their second quarter financial results released June 8, with both saying their earnings mark a return back to pre-pandemic form. Limoneira reported earnings of $1.5 million for the quarter, or 10 cents per share, up from a loss of $5.3 million in the Read More →
Amgen’s new drug could be a blockbuster
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Semtech shares up after company reports income and revenue growth
Semtech Corp., a Camarillo semiconductor company specializing in Internet of Things applications, saw its income and revenue rise in the first quarter of fiscal year 2021-22, thanks in large part to growth in its wireless and sensing products market. Semtech saw revenue rise 28% year-over-year to $170.4 million, the company said when it released its Read More →
Amgen reaches billion-dollar licensing deal with Japanese firm
Amgen announced an agreement June 1 with Kyowa Kirin, a Japanese pharmaceutical company, to jointly develop and commercialize a human monoclonal antibody that Kyowa Kirin is developing to treat atopic dermatitis and other autoimmune diseases. The deal could be worth $1.25 billion or more. Amgen will led the development, manufacturing and commercialization for the treatment, Read More →
Opinion: Remembering David Swensen, a giant in the investment world
By David Kreinces In early May, David Swensen, Yale’s legendary endowment chief, died of cancer at age 67. Swensen was famous on Wall Street for successfully diversifying Yale’s portfolio in a wide range of alternative investments, and he was also loved for his 2005 book on exchange-traded funds (ETFs). The book, “Unconventional Success,” showed Swensen’s Read More →
Amgen gets FDA approval for potential billion-dollar drug
Thousand Oaks-based Amgen won approval from the U.S. Food and Drug Administration on May 28 for its latest oral drug treatment, Lumakras, potentially adding another huge market for one of the largest biotech firms in the world. According to the Wall Street Journal, Amgen will charge $17,900 a month for the drug and analyst think Read More →
